lvgn6051
mAbexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2019 (NCT04130542)
Timeline
Indications
Mechanism of action
TNFRSF9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06378177 | Phase 2 | Jun 21, 2024 | Lyvgen Biopharma Holdings Limited, Shanghai Oriental Hospital |
| NCT05301764 | Phase 1/Phase 2 (Phase 2) | May 25, 2022 | Jiao Tong University, Lyvgen Biopharma Holdings Limited |
| NCT05075993 | Phase 1 | Nov 12, 2021 | Lyvgen Biopharma Holdings Limited, University of Texas at Houston |
| NCT04694781 | Phase 1 | Mar 10, 2021 | Lyvgen Biopharma Holdings Limited |
| NCT04130542 | Phase 1 | Oct 31, 2019 | Lyvgen Biopharma Holdings Limited |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lyvgen Biopharma Holdings Limited | For profit | 5 | 4 | 2 | 2019 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Shanghai Oriental Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1